GRUNENTHAL GMBH

Company Snapshot

Founded: 1946
Entity Type: Private
Employees: 4,100
Region: Europe
Revenue: $2,032.4 Millions
Revenue Year: 2025
Headquarter: Aachen, Germany
Key Geographics: Europe, Latin America, North America, Other Countries
Corporate Address: Zieglerstr. 6 52078 Aachen Germany Tel: +49-0241-5690 www.grunenthal.com

Company Overview

Grünenthal was founded in 1946 and is focused on developing and commercializing products in pain management, rheumatoid conditions, orthopedic disorders, neurological disorders, cancer and other related products. The company categorized its products into Growth Brands and Established Brands.

Financial Highlights (FY 2025)

Net Revenue: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

GRUNENTHAL GMBH In Reports

Global Market for Pain Management Drugs and Devices

BCC Research Market Report says global market for pain management drugs and devices is expected to increase from $84.6 billion in 2023 to $109.9 billion by the end of 2028, with a CAGR of 5.4%.

Transdermal Patches: Global Markets

BCC Research Market Report says transdermal patches is estimated to increase from $6.7 billion in 2022 to reach $8.8 billion by 2027, at a CAGR of 5.6%.

Topical Pain Relief Market

BCC Research Market Report says topical pain management drugs market should reach $12.5 billion by 2025 from $9.1 billion in 2020 at a compound annual growth rate of 6.6%.

Company's Business Segments

  • Products : Qutenza, Vimovo, Versatis, Zomig AscoTop Nasal, Nebido, Nexium, Crestor, Others
  • Services : Research and Development, Manufacturing Services, Product portfolio, Others

Applications/End User Industries

  • Pharmaceuticals
  • Biotechnology
  • Neurology
  • Oncology
  • Life Sciences
AI Sentiment